Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetrabromobenzimidazole
- Development stage
- Preclinical
- Lead developer
- Sigma Aldrich
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal
01
Overview
Tetrabromobenzimidazole (TBB) is a cell-permeable, selective, and ATP-competitive small molecule inhibitor of **Casein Kinase 2 (CK2)**. It is primarily utilized as a research tool to investigate the role of CK2 in various cellular processes, including signal transduction, cell cycle regulation, and apoptosis. In oncology research, TBB has been demonstrated to reduce the phosphorylation of the tumor suppressor **PTEN**, thereby restoring its activity and antagonizing the pro-survival PI3K/AKT signaling pathway. This mechanism is particularly relevant in the study of T-cell acute lymphoblastic leukemia (T-ALL), where CK2-mediated inactivation of PTEN often contributes to disease progression. TBB is widely available through research chemical suppliers and serves as a standard reference compound for CK2 inhibition in biochemical and cellular assays.
- Other names
- 4,5,6,7-tetrabromobenzimidazole4,5,6,7-tetrabromo-1H-benzimidazoleTBBz
02
Targets
CSNK1G3 (Casein kinase 1 gamma 3)CK2 (Casein kinase II subunit alpha)
Beyond the preview
Go deeper on tetrabromobenzimidazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetrabromobenzimidazole.